Arrowhead Pharmaceuticals Financials
0HI3 Stock | 18.55 0.04 0.22% |
Operating Margin (27.85) | Return On Equity (1.52) |
Arrowhead | Select Account or Indicator |
Understanding current and past Arrowhead Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Arrowhead Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Arrowhead Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Arrowhead Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arrowhead Pharmaceuticals Corp. Check Arrowhead Pharmaceuticals' Beneish M Score to see the likelihood of Arrowhead Pharmaceuticals' management manipulating its earnings.
Arrowhead Pharmaceuticals Stock Summary
Arrowhead Pharmaceuticals competes with Federal Realty, Silvercorp Metals, Lords Grp, Various Eateries, and Tatton Asset. Arrowhead Pharmaceuticals is entity of United Kingdom. It is traded as Stock on LSE exchange.Specialization | Industrials, Commercial & Professional Services |
Instrument | UK Stock View All |
Exchange | London Exchange |
Business Address | 177 East Colorado |
Sector | Commercial Services & Supplies |
Industry | Industrials |
Benchmark | Dow Jones Industrial |
Website | arrowheadpharma.com |
Phone | 626 304 3400 |
You should never invest in Arrowhead Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Arrowhead Stock, because this is throwing your money away. Analyzing the key information contained in Arrowhead Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Arrowhead Pharmaceuticals Key Financial Ratios
There are many critical financial ratios that Arrowhead Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Arrowhead Pharmaceuticals reports annually and quarterly.Revenue | 240.74 M | |||
Gross Profit | 240.74 M | |||
EBITDA | (175.67 M) | |||
Net Income | (209.28 M) | |||
Total Asset | 765.55 M |
Arrowhead Pharmaceuticals Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 522.5M | 710.1M | 691.9M | 765.6M | 880.4M | 924.4M | |
Other Current Liab | 32.8M | 33.3M | 100.4M | 58.2M | 66.9M | 70.2M | |
Net Debt | (122.4M) | (158.9M) | (26.4M) | 4.3M | 3.9M | 4.0M | |
Retained Earnings | (503.8M) | (644.7M) | (820.8M) | (1.0B) | (923.4M) | (877.3M) | |
Accounts Payable | 6.8M | 9.5M | 2.9M | 35.9M | 41.2M | 43.3M | |
Cash | 143.6M | 184.4M | 108.0M | 110.9M | 127.5M | 133.9M | |
Net Receivables | 661.4K | 845.7K | 10.3M | 1.4M | 1.6M | 971.4K | |
Inventory | 3.3M | 4.3M | 4.4M | (21.6M) | (19.5M) | (18.5M) | |
Other Current Assets | 6.0M | 6.6M | 27.5M | 15.9M | 18.3M | 19.2M | |
Total Liab | 60.7M | 301.3M | 586.0M | 478.4M | 550.1M | 577.7M | |
Total Current Assets | 322.4M | 384.6M | 376.4M | 419.5M | 482.4M | 506.6M | |
Short Term Debt | 1.1M | 4.5M | 5.6M | 10.6M | 12.1M | 12.8M | |
Common Stock | 194.7K | 197K | 106.0M | 200K | 230K | 218.5K | |
Intangible Assets | 15.4M | 13.7M | 12.0M | 10.3M | 11.8M | 10.2M | |
Other Liab | 1.9M | 8.7M | 131.5M | 56.0M | 64.3M | 44.0M | |
Net Tangible Assets | 446.4M | 395.2M | 386.6M | 261.1M | 300.2M | 291.5M | |
Capital Surpluse | 582.9M | 664.1M | 965.4M | 1.1B | 1.2B | 831.6M |
Arrowhead Pharmaceuticals Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Revenue | 88.0M | 138.3M | 243.2M | 240.7M | 276.8M | 290.7M | |
Gross Profit | 88.0M | 138.3M | 232.8M | 240.7M | 276.8M | 290.7M | |
Operating Income | (93.2M) | (149.0M) | (178.5M) | (205.0M) | (184.5M) | (175.3M) | |
Ebit | (93.2M) | (140.8M) | (172.7M) | (188.2M) | (169.3M) | (160.9M) | |
Ebitda | (87.2M) | (132.6M) | (162.3M) | (175.7M) | (158.1M) | (150.2M) | |
Income Before Tax | (84.6M) | (140.8M) | (172.7M) | (206.5M) | (185.8M) | (176.5M) | |
Net Income | (84.6M) | (140.8M) | (176.5M) | (205.3M) | (184.7M) | (175.5M) | |
Research Development | 128.9M | 206.3M | 297.3M | 353.2M | 406.2M | 426.5M | |
Interest Expense | 9.2B | 6.1M | 5.0M | 18.3M | 21.1M | 20.0M | |
Interest Income | 1.5M | 7.0M | 9.2M | 6.1M | 7.0M | 5.5M |
Arrowhead Pharmaceuticals Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (1.3M) | 1.6M | 9.2M | (3.4M) | (3.9M) | (4.1M) | |
Change In Cash | (78.2M) | 40.9M | (76.4M) | 2.9M | 3.3M | 4.5M | |
Free Cash Flow | (107.3M) | 147.7M | (188.9M) | (330.6M) | (297.6M) | (282.7M) | |
Depreciation | 5.9M | 8.3M | 10.4M | 12.5M | 14.4M | 15.1M | |
Other Non Cash Items | 525.3K | 266K | 7.3M | 16.3M | 18.8M | 19.7M | |
Capital Expenditures | 12.0M | 23.6M | 52.8M | 176.7M | 203.2M | 213.4M | |
Net Income | (84.6M) | (140.8M) | (176.5M) | (209.3M) | (188.3M) | (178.9M) | |
End Period Cash Flow | 143.6M | 184.4M | 108.0M | 110.9M | 127.5M | 133.9M | |
Investments | (228.8M) | (118.1M) | 47.4M | 80.6M | 92.7M | 97.3M | |
Change To Netincome | 43.9M | 75.2M | 127.8M | 90.4M | 104.0M | 57.5M |
Arrowhead Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arrowhead Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Arrowhead Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arrowhead Pharmaceuticals competition to find correlations between indicators driving Arrowhead Pharmaceuticals's intrinsic value. More Info.Arrowhead Pharmaceuticals Corp is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arrowhead Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Arrowhead Pharmaceuticals Systematic Risk
Arrowhead Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Arrowhead Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Arrowhead Pharmaceuticals correlated with the market. If Beta is less than 0 Arrowhead Pharmaceuticals generally moves in the opposite direction as compared to the market. If Arrowhead Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Arrowhead Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Arrowhead Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Arrowhead Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Arrowhead Pharmaceuticals Corp Total Assets Over Time
Arrowhead Pharmaceuticals November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Arrowhead Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Arrowhead Pharmaceuticals Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Arrowhead Pharmaceuticals Corp based on widely used predictive technical indicators. In general, we focus on analyzing Arrowhead Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arrowhead Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio | (0.12) | |||
Maximum Drawdown | 18.66 | |||
Value At Risk | (5.13) | |||
Potential Upside | 4.86 |
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.